John Alexander Kelly

Chief Financial Officer (principal financial and accounting officer), Precision BioSciences, Inc.

A later filing names a successor. First published here October 28, 2026; built from records as of October 28, 2026.

John Alexander Kelly signed the annual report of Precision BioSciences, Inc. on Form 10-K as Chief Financial Officer (principal financial and accounting officer), filed March 12, 2026.¹ A later filing by Precision BioSciences, Inc., made on July 27, 2026, names Naresh Tanna as its chief financial officer; the record holds no filing that reports the end of John Alexander Kelly's tenure.

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Precision BioSciences, Inc. (DTIL) Biological Products, (No Diagnostic Substances)	Chief Financial Officer (principal financial and accounting officer)	A later filing names a successor Naresh Tanna, filed July 27, 2026 (filing)	1

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

March 12, 202610-K filed
John Alexander Kelly signed the annual report of Precision BioSciences, Inc. on Form 10-K as Chief Financial Officer (principal financial and accounting officer), filed March 12, 2026.
/s/ John Alexander Kelly John Alexander Kelly Chief Financial Officer (principal financial and accounting officer)
[1] Annual report on Form 10-K by Precision BioSciences, Inc., filed with the SEC on March 12, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Precision BioSciences, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 12, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or John Alexander Kelly wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.